ID   SMAD7_HUMAN             Reviewed;         426 AA.
AC   O15105; O14740; Q6DK23;
DT   04-MAY-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   22-FEB-2012, entry version 125.
DE   RecName: Full=Mothers against decapentaplegic homolog 7;
DE            Short=MAD homolog 7;
DE            Short=Mothers against DPP homolog 7;
DE   AltName: Full=Mothers against decapentaplegic homolog 8;
DE            Short=MAD homolog 8;
DE            Short=Mothers against DPP homolog 8;
DE   AltName: Full=SMAD family member 7;
DE            Short=SMAD 7;
DE            Short=Smad7;
DE            Short=hSMAD7;
GN   Name=SMAD7; Synonyms=MADH7, MADH8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF 409-ARG--ARG-426.
RC   TISSUE=Umbilical vein endothelial cell;
RX   MEDLINE=97358542; PubMed=9215638; DOI=10.1016/S0092-8674(00)80303-7;
RA   Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.-Y., Grinnell B.W.,
RA   Richardson M.A., Topper J.N., Gimbrone M.A. Jr., Wrana J.L., Falb D.;
RT   "The MAD-related protein Smad7 associates with the TGFbeta receptor
RT   and functions as an antagonist of TGFbeta signaling.";
RL   Cell 89:1165-1173(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Umbilical vein endothelial cell;
RX   MEDLINE=97404392; PubMed=9256479; DOI=10.1073/pnas.94.17.9314;
RA   Topper J.N., Cai J., Qui Y., Anderson K.R., Xu Y.-Y., Deeds J.D.,
RA   Feeley R., Gimeno C.J., Woolf E.A., Tayber O., Mays G.G.,
RA   Sampson B.A., Schoen F.J., Gimbrone M.A. Jr., Falb D.;
RT   "Vascular MADs: two novel MAD-related genes selectively inducible by
RT   flow in human vascular endothelium.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:9314-9319(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=97474483; PubMed=9335507; DOI=10.1038/39369;
RA   Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L.,
RA   Heuchel R., Itoh S., Kawabata M., Heldin N.-E., Heldin C.-H.,
RA   ten Dijke P.;
RT   "Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta
RT   signalling.";
RL   Nature 389:631-635(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Hagiwara K., Yang K., McMenamin M.G., Freeman A.H., Bennett W.P.,
RA   Nagashima M., Minter A.R., Miyazono K., Takenoshita S., Harris C.C.;
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   REVIEW.
RX   MEDLINE=98431667; PubMed=9759503;
RX   DOI=10.1146/annurev.biochem.67.1.753;
RA   Massague J.;
RT   "TGF-beta signal transduction.";
RL   Annu. Rev. Biochem. 67:753-791(1998).
RN   [7]
RP   REVIEW.
RX   MEDLINE=20112302; PubMed=10647776; DOI=10.1016/S1359-6101(99)00012-X;
RA   Verschueren K., Huylebroeck D.;
RT   "Remarkable versatility of Smad proteins in the nucleus of
RT   transforming growth factor-beta activated cells.";
RL   Cytokine Growth Factor Rev. 10:187-199(1999).
RN   [8]
RP   INTERACTION WITH ACVR1B, AND FUNCTION.
RX   PubMed=9892009; DOI=10.1210/me.13.1.15;
RA   Lebrun J.J., Takabe K., Chen Y., Vale W.;
RT   "Roles of pathway-specific and inhibitory Smads in activin receptor
RT   signaling.";
RL   Mol. Endocrinol. 13:15-23(1999).
RN   [9]
RP   REVIEW.
RX   MEDLINE=20175821; PubMed=10708948; DOI=10.1016/S1359-6101(99)00024-6;
RA   Wrana J.L., Attisano L.;
RT   "The Smad pathway.";
RL   Cytokine Growth Factor Rev. 11:5-13(2000).
RN   [10]
RP   REVIEW.
RX   MEDLINE=20175822; PubMed=10708949; DOI=10.1016/S1359-6101(99)00025-8;
RA   Miyazono K.;
RT   "TGF-beta signaling by Smad proteins.";
RL   Cytokine Growth Factor Rev. 11:15-22(2000).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF TYR-211 AND 207-PRO--TYR-211, AND INTERACTION
RP   WITH SMURF2 AND TGFBR1.
RX   MEDLINE=21111046; PubMed=11163210; DOI=10.1016/S1097-2765(00)00134-9;
RA   Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H.,
RA   Thomsen G.H., Wrana J.L.;
RT   "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the
RT   TGF-beta receptor for degradation.";
RL   Mol. Cell 6:1365-1375(2000).
RN   [12]
RP   INTERACTION WITH STAMBP.
RX   PubMed=11483516; DOI=10.1093/emboj/20.15.4132;
RA   Itoh F., Asao H., Sugamura K., Heldin C.-H., ten Dijke P., Itoh S.;
RT   "Promoting bone morphogenetic protein signaling through negative
RT   regulation of inhibitory Smads.";
RL   EMBO J. 20:4132-4142(2001).
RN   [13]
RP   INTERACTION WITH SMURF1 AND TGFBR1, AND PROTEASOMAL DEGRADATION.
RX   PubMed=11278251; DOI=10.1074/jbc.C100008200;
RA   Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T.,
RA   Miyazono K.;
RT   "Smurf1 interacts with transforming growth factor-beta type I receptor
RT   through Smad7 and induces receptor degradation.";
RL   J. Biol. Chem. 276:12477-12480(2001).
RN   [14]
RP   INTERACTION WITH ACVR1B, AND FUNCTION.
RX   PubMed=12023024; DOI=10.1016/S0014-5793(02)02718-7;
RA   Liu X., Nagarajan R.P., Vale W., Chen Y.;
RT   "Phosphorylation regulation of the interaction between Smad7 and
RT   activin type I receptor.";
RL   FEBS Lett. 519:93-98(2002).
RN   [15]
RP   INTERACTION WITH EP300, ACETYLATION AT LYS-64 AND LYS-70,
RP   UBIQUITINATION AT LYS-64 AND LYS-70, AND MUTAGENESIS OF LYS-64 AND
RP   LYS-70.
RX   PubMed=12408818; DOI=10.1016/S1097-2765(02)00639-1;
RA   Gronroos E., Hellman U., Heldin C.H., Ericsson J.;
RT   "Control of Smad7 stability by competition between acetylation and
RT   ubiquitination.";
RL   Mol. Cell 10:483-493(2002).
RN   [16]
RP   INTERACTION WITH RNF111, UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=14657019; DOI=10.1093/emboj/cdg632;
RA   Koinuma D., Shinozaki M., Komuro A., Goto K., Saitoh M., Hanyu A.,
RA   Ebina M., Nukiwa T., Miyazawa K., Imamura T., Miyazono K.;
RT   "Arkadia amplifies TGF-beta superfamily signaling through degradation
RT   of Smad7.";
RL   EMBO J. 22:6458-6470(2003).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH PPP1R15A.
RX   PubMed=14718519; DOI=10.1083/jcb.200307151;
RA   Shi W., Sun C., He B., Xiong W., Shi X., Yao D., Cao X.;
RT   "GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I
RT   receptor.";
RL   J. Cell Biol. 164:291-300(2004).
RN   [18]
RP   INTERACTION WITH COPS5.
RX   PubMed=14993265; DOI=10.1128/MCB.24.6.2251-2262.2004;
RA   Kim B.-C., Lee H.-J., Park S.H., Lee S.R., Karpova T.S., McNally J.G.,
RA   Felici A., Lee D.K., Kim S.-J.;
RT   "Jab1/CSN5, a component of the COP9 signalosome, regulates
RT   transforming growth factor beta signaling by binding to Smad7 and
RT   promoting its degradation.";
RL   Mol. Cell. Biol. 24:2251-2262(2004).
RN   [19]
RP   INTERACTION WITH SMURF2.
RX   PubMed=16061177; DOI=10.1016/j.molcel.2005.06.028;
RA   Ogunjimi A.A., Briant D.J., Pece-Barbara N., Le Roy C.,
RA   Di Guglielmo G.M., Kavsak P., Rasmussen R.K., Seet B.T., Sicheri F.,
RA   Wrana J.L.;
RT   "Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to
RT   the HECT domain.";
RL   Mol. Cell 19:297-308(2005).
RN   [20]
RP   INTERACTION WITH AXIN1 AND AXIN2, UBIQUITINATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16601693; DOI=10.1038/sj.emboj.7601057;
RA   Liu W., Rui H., Wang J., Lin S., He Y., Chen M., Li Q., Ye Z.,
RA   Zhang S., Chan S.C., Chen Y.-G., Han J., Lin S.-C.;
RT   "Axin is a scaffold protein in TGF-beta signaling that promotes
RT   degradation of Smad7 by Arkadia.";
RL   EMBO J. 25:1646-1658(2006).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION BY PDPK1, AND
RP   INTERACTION WITH PDPK1.
RX   PubMed=17327236; DOI=10.1074/jbc.M609279200;
RA   Seong H.A., Jung H., Kim K.T., Ha H.;
RT   "3-Phosphoinositide-dependent PDK1 negatively regulates transforming
RT   growth factor-beta-induced signaling in a kinase-dependent manner
RT   through physical interaction with Smad proteins.";
RL   J. Biol. Chem. 282:12272-12289(2007).
RN   [22]
RP   STRUCTURE BY NMR OF 203-217 IN COMPLEX WITH SMURF2.
RX   PubMed=16641086; DOI=10.1074/jbc.M601493200;
RA   Chong P.A., Lin H., Wrana J.L., Forman-Kay J.D.;
RT   "An expanded WW domain recognition motif revealed by the interaction
RT   between Smad7 and the E3 ubiquitin ligase Smurf2.";
RL   J. Biol. Chem. 281:17069-17075(2006).
RN   [23]
RP   INVOLVEMENT IN CRCS3.
RX   PubMed=17934461; DOI=10.1038/ng.2007.18;
RG   Members of the CORGI consortium;
RA   Broderick P., Carvajal-Carmona L., Pittman A.M., Webb E., Howarth K.,
RA   Rowan A., Lubbe S., Spain S., Sullivan K., Fielding S., Jaeger E.,
RA   Vijayakrishnan J., Kemp Z., Gorman M., Chandler I., Papaemmanuil E.,
RA   Penegar S., Wood W., Sellick G., Qureshi M., Teixeira A., Domingo E.,
RA   Barclay E., Martin L., Sieber O., Kerr D., Gray R., Peto J.,
RA   Cazier J.-B., Tomlinson I., Houlston R.S.;
RT   "A genome-wide association study shows that common alleles of SMAD7
RT   influence colorectal cancer risk.";
RL   Nat. Genet. 39:1315-1317(2007).
CC   -!- FUNCTION: Antagonist of signaling by TGF-beta (transforming growth
CC       factor) type 1 receptor superfamily members; has been shown to
CC       inhibit TGF-beta (Transforming growth factor) and activin
CC       signaling by associating with their receptors thus preventing
CC       SMAD2 access. Functions as an adapter to recruit SMURF2 to the
CC       TGF-beta receptor complex. Also acts by recruiting the PPP1R15A-
CC       PP1 complex to TGFBR1, which promotes its dephosphorylation.
CC       Positively regulates PDPK1 kinase activity by stimulating its
CC       dissociation from the 14-3-3 protein YWHAQ which acts as a
CC       negative regulator (By similarity).
CC   -!- SUBUNIT: Interacts with WWP1 (By similarity). Interacts with
CC       COPS5. Interacts with NEDD4L. Interacts with STAMBP. Interacts
CC       with RNF111, AXIN1 and AXIN2. Interacts with PPP1R15A. Interacts
CC       (via MH2 domain) with EP300. Interacts with ACVR1B, SMURF1, SMURF2
CC       and TGFBR1; SMAD7 recruits SMURF1 and SMURF2 to the TGF-beta
CC       receptor and regulates its degradation. Interacts with PDPK1 (via
CC       PH domain).
CC   -!- INTERACTION:
CC       Q92905:COPS5; NbExp=10; IntAct=EBI-3861591, EBI-594661;
CC       O00308:WWP2; NbExp=5; IntAct=EBI-3861591, EBI-743923;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Interaction with
CC       NEDD4L or RNF111 or induces translocation from the nucleus to the
CC       cytoplasm. TGF-beta stimulates its translocation from the nucleus
CC       to the cytoplasm. PDPK1 inhibits its translocation from the
CC       nucleus to the cytoplasm in response to TGF-beta.
CC   -!- TISSUE SPECIFICITY: Ubiquitous with higher expression in the lung
CC       and vascular endothelium.
CC   -!- INDUCTION: By TGFB1.
CC   -!- PTM: Phosphorylation on Ser-249 does not affect its stability,
CC       nuclear localization or inhibitory function in TGFB signaling;
CC       however it affects its ability to regulate transcription (By
CC       similarity). Phosphorylated by PDPK1.
CC   -!- PTM: Ubiquitinated by WWP1 (By similarity). Polyubiquitinated by
CC       RNF111, which is enhanced by AXIN1 and promotes proteasomal
CC       degradation. In response to TGF-beta, ubiquitinated by SMURF1;
CC       which promotes its degradation.
CC   -!- PTM: Acetylation prevents ubiquitination and degradation mediated
CC       by SMURF1.
CC   -!- DISEASE: Genetic variations in SMAD7 influence susceptibility to
CC       colorectal cancer type 3 (CRCS3) [MIM:612229]. Colorectal cancer
CC       consists of tumors or cancer of either the colon or rectum or
CC       both. Cancers of the large intestine are the second most common
CC       form of cancer found in males and females. Symptoms include rectal
CC       bleeding, occult blood in stools, bowel obstruction and weight
CC       loss. Treatment is based largely on the extent of cancer
CC       penetration into the intestinal wall. Surgical cures are possible
CC       if the malignancy is confined to the intestine. Risk can be
CC       reduced when following a diet which is low in fat and high in
CC       fiber.
CC   -!- SIMILARITY: Belongs to the dwarfin/SMAD family.
CC   -!- SIMILARITY: Contains 1 MH1 (MAD homology 1) domain.
CC   -!- SIMILARITY: Contains 1 MH2 (MAD homology 2) domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF010193; AAB81246.1; -; mRNA.
DR   EMBL; AF015261; AAB81354.1; -; mRNA.
DR   EMBL; AF026559; AAL68977.1; -; Genomic_DNA.
DR   EMBL; AF026556; AAL68977.1; JOINED; Genomic_DNA.
DR   EMBL; AF026557; AAL68977.1; JOINED; Genomic_DNA.
DR   EMBL; AF026558; AAL68977.1; JOINED; Genomic_DNA.
DR   EMBL; BC074818; AAH74818.2; -; mRNA.
DR   EMBL; BC074819; AAH74819.2; -; mRNA.
DR   IPI; IPI00005079; -.
DR   RefSeq; NP_001177750.1; NM_001190821.1.
DR   RefSeq; NP_001177751.1; NM_001190822.1.
DR   RefSeq; NP_001177752.1; NM_001190823.1.
DR   RefSeq; NP_005895.1; NM_005904.3.
DR   UniGene; Hs.465087; -.
DR   PDB; 2DJY; NMR; -; B=203-217.
DR   PDBsum; 2DJY; -.
DR   ProteinModelPortal; O15105; -.
DR   SMR; O15105; 86-203, 254-426.
DR   IntAct; O15105; 3.
DR   MINT; MINT-1179821; -.
DR   STRING; O15105; -.
DR   PhosphoSite; O15105; -.
DR   PRIDE; O15105; -.
DR   Ensembl; ENST00000262158; ENSP00000262158; ENSG00000101665.
DR   GeneID; 4092; -.
DR   KEGG; hsa:4092; -.
DR   UCSC; uc002ldg.1; human.
DR   CTD; 4092; -.
DR   GeneCards; GC18M046446; -.
DR   H-InvDB; HIX0039705; -.
DR   HGNC; HGNC:6773; SMAD7.
DR   HPA; CAB026212; -.
DR   HPA; HPA028897; -.
DR   MIM; 602932; gene.
DR   MIM; 612229; phenotype.
DR   neXtProt; NX_O15105; -.
DR   PharmGKB; PA134875286; -.
DR   eggNOG; NOG309572; -.
DR   GeneTree; ENSGT00600000084353; -.
DR   HOGENOM; HBG715578; -.
DR   HOVERGEN; HBG053021; -.
DR   InParanoid; O15105; -.
DR   KO; K04677; -.
DR   OMA; CSENKSQ; -.
DR   OrthoDB; EOG41G34G; -.
DR   PhylomeDB; O15105; -.
DR   Pathway_Interaction_DB; bmppathway; BMP receptor signaling.
DR   Pathway_Interaction_DB; ifngpathway; IFN-gamma pathway.
DR   Pathway_Interaction_DB; smad2_3nuclearpathway; Regulation of nuclear SMAD2/3 signaling.
DR   Pathway_Interaction_DB; hdac_classi_pathway; Signaling events mediated by HDAC Class I.
DR   Pathway_Interaction_DB; tgfbrpathway; TGF-beta receptor signaling.
DR   Reactome; REACT_111102; Signal Transduction.
DR   NextBio; 16046; -.
DR   ArrayExpress; O15105; -.
DR   Bgee; O15105; -.
DR   CleanEx; HS_SMAD7; -.
DR   Genevestigator; O15105; -.
DR   GermOnline; ENSG00000101665; Homo sapiens.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005667; C:transcription factor complex; IEA:InterPro.
DR   GO; GO:0048185; F:activin binding; IPI:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0030617; F:transforming growth factor beta receptor, inhibitory cytoplasmic mediator activity; IDA:BHF-UCL.
DR   GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IPI:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0034333; P:adherens junction assembly; IMP:BHF-UCL.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; TAS:Reactome.
DR   GO; GO:0034629; P:cellular protein complex localization; IDA:BHF-UCL.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; TAS:BHF-UCL.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; TAS:BHF-UCL.
DR   GO; GO:0060394; P:negative regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0010801; P:negative regulation of peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051444; P:negative regulation of ubiquitin-protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0045768; P:positive regulation of anti-apoptosis; TAS:BHF-UCL.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL.
DR   GO; GO:0032925; P:regulation of activin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0060373; P:regulation of ventricular cardiomyocyte membrane depolarization; IC:BHF-UCL.
DR   GO; GO:0034616; P:response to laminar fluid shear stress; IEP:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL.
DR   InterPro; IPR013790; Dwarfin.
DR   InterPro; IPR003619; MAD_homology1_Dwarfin-type.
DR   InterPro; IPR013019; MAD_homology_MH1.
DR   InterPro; IPR017855; SMAD_dom-like.
DR   InterPro; IPR001132; SMAD_dom_Dwarfin-type.
DR   InterPro; IPR008984; SMAD_FHA_domain.
DR   Gene3D; G3DSA:3.90.520.10; MAD_MH1; 2.
DR   Gene3D; G3DSA:2.60.200.10; MH2_Dwarfin-type; 1.
DR   PANTHER; PTHR13703; Dwarfin; 1.
DR   Pfam; PF03165; MH1; 1.
DR   Pfam; PF03166; MH2; 1.
DR   SMART; SM00523; DWA; 1.
DR   SMART; SM00524; DWB; 1.
DR   SUPFAM; SSF56366; MAD_MH1; 1.
DR   SUPFAM; SSF49879; SMAD_FHA; 1.
DR   PROSITE; PS51075; MH1; 1.
DR   PROSITE; PS51076; MH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN         1    426       Mothers against decapentaplegic homolog
FT                                7.
FT                                /FTId=PRO_0000090872.
FT   DOMAIN       64    207       MH1.
FT   DOMAIN      261    426       MH2.
FT   REGION      208    217       Important for interaction with SMURF2.
FT   MOTIF       208    211       PY-motif.
FT   COMPBIAS     27     35       Poly-Gly.
FT   COMPBIAS     49     56       Poly-Gly.
FT   COMPBIAS    207    210       Poly-Pro.
FT   MOD_RES      64     64       N6-acetyllysine; alternate.
FT   MOD_RES      70     70       N6-acetyllysine; alternate.
FT   MOD_RES     249    249       Phosphoserine (By similarity).
FT   CROSSLNK     64     64       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate.
FT   CROSSLNK     70     70       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate.
FT   MUTAGEN      64     64       K->A: Loss of acetylation, and of SMURF1-
FT                                dependent degradation; when associated
FT                                with A-70.
FT   MUTAGEN      70     70       K->A: Loss of acetylation, and of SMURF1-
FT                                dependent degradation; when associated
FT                                with A-64.
FT   MUTAGEN     207    211       Missing: Diminishes interaction with
FT                                SMURF2.
FT   MUTAGEN     211    211       Y->A: Diminishes interaction with SMURF2
FT                                and reduces inhibition of TGF-beta
FT                                signaling.
FT   MUTAGEN     409    426       Missing: 90% reduction in TGF-beta
FT                                receptor binding.
FT   CONFLICT     71     71       G -> C (in Ref. 3; AAB81354).
FT   STRAND      204    206
FT   STRAND      212    214
SQ   SEQUENCE   426 AA;  46426 MW;  5B76EC986776C102 CRC64;
     MFRTKRSALV RRLWRSRAPG GEDEEEGAGG GGGGGELRGE GATDSRAHGA GGGGPGRAGC
     CLGKAVRGAK GHHHPHPPAA GAGAAGGAEA DLKALTHSVL KKLKERQLEL LLQAVESRGG
     TRTACLLLPG RLDCRLGPGA PAGAQPAQPP SSYSLPLLLC KVFRWPDLRH SSEVKRLCCC
     ESYGKINPEL VCCNPHHLSR LCELESPPPP YSRYPMDFLK PTADCPDAVP SSAETGGTNY
     LAPGGLSDSQ LLLEPGDRSH WCVVAYWEEK TRVGRLYCVQ EPSLDIFYDL PQGNGFCLGQ
     LNSDNKSQLV QKVRSKIGCG IQLTREVDGV WVYNRSSYPI FIKSATLDNP DSRTLLVHKV
     FPGFSIKAFD YEKAYSLQRP NDHEFMQQPW TGFTVQISFV KGWGQCYTRQ FISSCPCWLE
     VIFNSR
//
